US20230064429A1 - IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS - Google Patents

IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS Download PDF

Info

Publication number
US20230064429A1
US20230064429A1 US17/890,198 US202217890198A US2023064429A1 US 20230064429 A1 US20230064429 A1 US 20230064429A1 US 202217890198 A US202217890198 A US 202217890198A US 2023064429 A1 US2023064429 A1 US 2023064429A1
Authority
US
United States
Prior art keywords
chosen
lsd
group
composition
starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/890,198
Other languages
English (en)
Inventor
Peter Mack
Dustin MELTON
Bethany Amber DOTY
Jon Schroeder
James Coghill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mind Medicine Inc
Original Assignee
Mind Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mind Medicine Inc filed Critical Mind Medicine Inc
Priority to US17/890,198 priority Critical patent/US20230064429A1/en
Assigned to Mind Medicine, Inc. reassignment Mind Medicine, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COGHILL, JAMES, MELTON, Dustin, SCHROEDER, JON, LEVY, DANIEL EMIL, DOTY, Bethany Amber, MACK, PETER
Priority to US18/077,096 priority patent/US20230107398A1/en
Publication of US20230064429A1 publication Critical patent/US20230064429A1/en
Priority to US18/199,244 priority patent/US20230285386A1/en
Assigned to Definium Therapeutics US, Inc. reassignment Definium Therapeutics US, Inc. CHANGE OF NAME Assignors: Mind Medicine, Inc.
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Definitions

  • the present invention relates to the formulation of drugs. More specifically, the present invention relates to an immediate release formulation for a pharmaceutical formulation of d-lysergic acid diethylamide (LSD).
  • LSD d-lysergic acid diethylamide
  • Oral solution formulations are convenient for studies in a small number of sites and with a limited number of patients, mainly early phase development studies, but may not be suitable for later phase development studies run in many centers and across wide geographies nor for commercialization due to challenges in product stability and supply chain, such as the potential requirement for cold chain storage.
  • Solid oral formulations as tablets or capsules are more common in later phase clinical development and commercially due to advantages in production, supply chain, and patient convenience.
  • Solid oral formulations can be immediate release, dissolving instantaneously in the mouth or stomach, or extended release in which the drug release is prolonged over time.
  • Orally disintegrating tablets are another solid dosage form which is formulated with the aim of increasing the dissolution rate of a pharmaceutical product and promoting pre-gastric absorption.
  • the ODT formulation In order to achieve rapid disintegration rates, the ODT formulation must provide high porosity, low density, and a low hardness (Berthoumieu et al., 2010; Bandari et al., 2008).
  • This dosage form can be chosen to modify absorption or for patient populations that have difficulty in swallowing (Lindgren et al., 1993), and is also suitable for use in geriatric and pediatric patients, or for those who suffer from conditions such as dysphagia (Sastry et al., 2000).
  • LSD is derived from its German name LysergSaureDiethylamid (Lysergic acid diethylamide). Lysergide belongs to a family of indole alkylamines that includes numerous substituted tryptamines such as psilocin (the active moiety of psilocybin) and N,N-dimethyltryptamine (DMT). The IUPAC name for LSD is 9,10-didehydro-N,N-diethyl-6-methylergoline-8 ⁇ -carboxamide.
  • LSD can be used to assist psychotherapy for many indications including anxiety, depression, addiction, personality disorder, and others and can also be used to treat other disorders such as cluster headache, migraine, and others (Passie et al., 2008; Hintzen et al., 2010; Nichols, 2016; Liechti, 2017). Effects of LSD can include altered thoughts, feelings, awareness of surroundings, dilated pupils, increased blood pressure, and increased body temperature. Therapeutic use of LSD is showing promising results for treating various neurological and behavioral disorders. However, due to its potency there can be challenges in developing and manufacturing solid oral formulations of LSD that meet pharmaceutically acceptable limits for content uniformity and chemical stability.
  • LSD d-Lysergic Acid Diethylamide
  • the final drug product should be in a form that is easily administered to a broad range of patient populations, including, but not limited to the elderly, pediatrics, and patients with a condition that may limit their ability to swallow.
  • the present invention provides a solid oral immediate release formulation of LSD, including LSD formulations intended for a capsule, tablet, or orally disintegrating tablet dosage form.
  • the present invention further provides a method of making a solid oral immediate release formulation of LSD using processes such as granulation and blending that are uniform, chemically stable, and dissolve rapidly.
  • the present invention also provides for a method of treating an individual by administering a solid oral immediate release formulation of LSD.
  • FIG. 1 is a representation of D-LSD D-tartrate salt
  • FIG. 2 is a graph of LSD content uniformity from a solid oral capsule formulation made by granulation
  • FIG. 3 is a graph showing the immediate release of LSD from a solid oral capsule formulation made by granulation.
  • FIG. 4 is a graph showing chemical stability of LSD when blended as a solid drug crystal with lactose, microcrystalline cellulose, or mannitol.
  • the present invention provides for a formulation of LSD in a quick or immediate release dosage form such as a capsule, tablet, or orally disintegrating tablet.
  • the term “quick release tablet” is a mechanism that (similar to immediate-release dosage) delivers a drug immediately in contrast with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release (ER, XR, XL) dosage) or to a specific target in the body (targeted-release dosage). Preferably, it refers to minimal time dependent release in oral dose formulations.
  • the present invention provides a composition, preferably including LSD as its active, or one of its active ingredients, that dissolves relatively quickly once orally ingested. This provides an easy to administer yet anticipated to be effective and efficacious therapeutic effect.
  • the LSD can be in a free base form or a salt form as a crystalline or non-crystalline solid.
  • the salt can be, but is not limited to, hydrochloride, hydrobromide, maleate, tartrate (including D-tartrate and meso-tartrate), citrate, phosphate, fumarate, sulfate, mesylate, acetate, oxalate, benzoate, benzensulfonate, xinafoate, 1,5-Napthalene disulfonate, ascorbate, and naphthalene-2-sulfonate.
  • the dose of LSD can preferably be 0.01-1 mg (10-1000 ⁇ g). However, dosing can be adjusted depending on indication, age, weight, and other factors affecting the pharmacology, physiology, and drug/drug interactions in a given patient.
  • Solid oral formulations typically contain secondary ingredient components known as excipients which can include but are not limited to fillers/bulking agents, binders, absorbents, disintegrants, glidants, lubricants, pH modifiers/buffers, preservatives, antioxidants, permeation enhancers, coloring agents, and sweeteners/flavoring agents. Examples of each are listed below and some common excipients serve more than one function.
  • fillers used in solid oral formulations include lactose (including anhydrous), mannitol, dicalcium phosphate, calcium sulfate, starch (starch as used herein can include dry or pre-gelled), cellulose (including microcrystalline cellulose), kaolin, sodium chloride, sorbitol, trehalose, sucrose, etc.
  • Binders which are polymeric, natural, or synthetic materials that impart cohesive qualities to powdered materials, can also be included. Binders must be non-toxic and must have a good compatibility profile. Materials commonly used as binders include acacia gum, methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, tragacanth, polyvinyl pyrrolidone (PVP), starch, etc. Microcrystalline cellulose is also considered a dry binder.
  • Excipients such as starch, colloidal or mesoporous silicon dioxide (i.e. silica), sodium starch glycolate, and microcrystalline cellulose can act as solvent absorbents or disintegrants by absorbing solvents such as water while increasing the formulation wettability. Some of these excipients can be preferred for either absorbent of disintegrant properties but can also include the other property.
  • partially pre-gelled starch e.g., Starch 1500
  • Starch 1500 is often used as a disintegrant, but is also used as an absorbent to scavenge moisture to gorge' the moisture from drugs that are sensitive to it.
  • Starch 1500 When Starch 1500 is used as an absorbent in moisture activated dry granulation (MADG) it loses some of its disintegrant capability, but if it is added after the absorbent stage it can function as a disintegrant.
  • Colloidal (or mesoporous) silicon dioxide can be an excellent absorbent but can be a weak disintegrant.
  • Sodium starch glycolate can be an excellent disintegrant.
  • Microcrystalline cellulose is an excellent absorbent and can have disintegrant properties. Croscarmellose sodium, crospovidone, sodium starch glycolate (which are disintegrants) and starch swell in the presence of aqueous fluids, thereby facilitating tablet disintegration due to the increase in the internal pressure within the tablet matrix.
  • Glidants enhance the flowability of a formulation.
  • Typical glidants include magnesium stearate, colloidal silicon dioxide, etc.
  • the hydrophobic stearic acid and stearic acid salts e.g., magnesium stearate and sodium stearyl fumarate, are the most widely used lubricants in oral drug formulations. They are typically added at concentrations less than 2% w/w in order to minimize any deleterious effect on formulation matrix disintegration or dissolution.
  • Other examples of lubricants used include polyethylene glycol (PEG), polyoxyethylene stearates, lauryl sulphate salts, talc, glyceryl behenate, glyceryl palmitostearate, calcium stearate, hydrogenated vegetable oils etc.
  • Buffer is added to target the formulation to a specific pH.
  • three buffers, citrate, phosphate, and acetate make up the majority of buffers used in pharmaceuticals approved by the FDA, but less precedented excipients are certainly available to use in commercial dosage forms.
  • the pH of a formulation alternatively can be adjusted with unbuffered acid (i.e. hydrochloric acid) or unbuffered base (i.e. sodium hydroxide).
  • Antioxidants can be added to the formulation in order to minimize degradation due to oxidative stress.
  • the term oxidation can be defined as the incorporation of oxygen into the structure of a drug, or as the process of converting one chemical substance into another derivative bearing a smaller number of electrons.
  • antioxidants are ascorbic acid, citric acid, butylatedhydroxy anisole (BHA), and butylated hydroxytoluene (BHT).
  • the photostability of a drug substance can be defined as the response of the drug or drug product to the exposure to solar, UV, and visible light in the solid, semisolid, or liquid state that leads to a physical or chemical change. Undue light exposure can result in potency loss, altered efficacy, and adverse biological effects.
  • Various additives or encapsulation methods and compositions can be used to protect the active product from light in order to minimize any degradation due to light exposure (i.e. photostabilization agents).
  • liposomes are microscopic and submicroscopic phospholipid vesicles with a bilayered membrane structure. Photostabilization of the drug substance by entrapment into liposomes is one such way to improve their photostability.
  • Photo degradation can also occur in combination with oxygen exposure, resulting in photo-oxidation degradation.
  • Some of the commonly used antioxidants to protect against photo-oxidation are ascorbic acid, ⁇ -tocopherol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), L-histidine, propyl gallate, and sulfur compounds.
  • Ascorbic acid, ⁇ -tocopherol, ⁇ -carotene, and BHT act as free radical scavengers and singlet oxygen quenchers and thus inhibit the photosensitization reactions. If a drug substance acts as a photosensitizer and initiates a chain reaction in the drug product, some of the excipients can be oxidized, while the drug can be protected from photodegradation.
  • the formulation can also contain permeability enhancers to increase the extent and/or rate of absorption.
  • enhancers are sulphoxides (such as dimethyl sulphoxide, DMSO), azones (e.g. laurocapram), pyrrolidones (for example 2-pyrrolidone, 2P), alcohols and alkanols (ethanol, or decanol), glycols (for example propylene glycol, PG, a common excipient in topically applied dosage forms), surfactants (also common in dosage forms) and terpenes.
  • sulphoxides such as dimethyl sulphoxide, DMSO
  • azones e.g. laurocapram
  • pyrrolidones for example 2-pyrrolidone, 2P
  • alcohols and alkanols ethanol, or decanol
  • glycols for example propylene glycol, PG, a common excipient in topically applied dosage forms
  • Coloring agents can also be added to solid oral formulations in order to improve patient recognition and acceptability.
  • Immediate release formulations produced by granulation can contain but are not limited to the solid oral formulation fillers/bulking agents, binders, absorbents, disintegrants, glidants, and lubricants as described above as well as buffers, antioxidants, absorption enhancers, and coloring and flavoring agents.
  • One such granulation process is high shear granulation whereby powders (active, dry binders, fillers, etc.) are charged to a closed container which contains mixing/blending components such as an impeller and chopper.
  • wet granulation hereafter referred to as wet granulation, the powders are wetted with a binder solution/suspension while mixing allowing for particle cohesion and granule growth.
  • excipients can be added and mixed with the granules after the binder solution/suspension addition.
  • concentration of the active it is typically added either as a dry ingredient (higher concentrations of active ingredient typically greater than 1-10% by weight) prior to the binder solution/suspension addition or contained within the binder solution/suspension (lower concentrations of active ingredient typically less than 1-10% by weight) to ensure uniformity.
  • wet granulation when active is added in solution or suspension the liquid solvent is removed by active drying.
  • MADG moisture activated dry granulation
  • the liquid (typically water) content is reduced and taken up by absorbents added to the formulation rather than introducing an active drying step.
  • Dry blending of crystalline API is an alternative solid oral formulation approach to granulation, further described in EXAMPLE 2. Dry blending can employ similar mixing/blending equipment as granulation or with lower shear mixing and can use similar excipient classes, minimally with a filler. Dry blending formulations can be further processed into tablets including orally disintegrating tablets through direct compression or encapsulated. When forming for direct compression, the composition can also include any of the binders, disintegrants, glidants, and lubricants described above as needed for processing.
  • the compound of the present invention is administered and dosed considering the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners.
  • the pharmaceutically “effective amount” for purposes herein is thus determined by such considerations as are known in the art. The amount must be effective to achieve improvement including but not limited to improved survival rate or more rapid recovery, or improvement or elimination of symptoms and other indicators as are selected as appropriate measures by those skilled in the art.
  • the compound of the present invention can be administered in various ways. It should be noted that it can be administered as the compound and can be administered alone or as an active ingredient in combination with pharmaceutically acceptable carriers, diluents, adjuvants, and vehicles.
  • the patient being treated is a warm-blooded animal and, in particular, mammals including humans.
  • the pharmaceutically acceptable carriers, diluents, adjuvants, and vehicles generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating material not reacting with the active ingredients of the invention.
  • the doses can be single doses or multiple doses over a period of several days.
  • the treatment generally has a length proportional to the length of the disease process and drug effectiveness and the patient species being treated.
  • Drug absorption is determined by the drug's physicochemical properties, formulation, and route of administration.
  • Dosage forms e.g., tablets, capsules, solutions
  • drugs are formulated to be given by various routes (e.g., oral, buccal, sublingual, rectal, parenteral, topical, inhalational).
  • routes e.g., oral, buccal, sublingual, rectal, parenteral, topical, inhalational.
  • drugs must be in solution to be absorbed.
  • solid forms e.g., tablets, capsules
  • Solid oral tablets and capsule formulations typically have gastric absorption, whereas an ODT formulation can be formulated to target pre-gastric or buccal absorption which can further enhance bioavailability.
  • the present invention provides for a method of making a solid oral immediate release formulation of LSD, as a free base or in a salt form, by a step chosen from 1) granulating with excipients such as fillers, absorbents, binders, disintegrants, glidants, and/or lubricants to encapsulate or form a tablet; or 2) blending with excipients such as fillers, disintegrants, dry binders, glidants, and/or lubricants for direct compression into tablets, including ODTs, or encapsulation.
  • excipients such as fillers, absorbents, binders, disintegrants, glidants, and/or lubricants
  • the present invention provides for a method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual.
  • the condition or disease being treated can include, but is not limited to, anxiety disorders (including anxiety in advanced stage illness e.g. cancer, as well as generalized anxiety disorder), depression (including postpartum depression, major depressive disorder and treatment-resistant depression), headache disorder (including cluster headaches and migraine headache), obsessive compulsive disorder (OCD), personality disorders (including conduct disorder), stress disorders (including adjustment disorders and post-traumatic stress disorder), drug disorders (including alcohol dependence or withdrawal, nicotine dependence or withdrawal, opioid dependence or withdrawal, cocaine dependence or withdrawal, methamphetamine dependence or withdrawal), other addictions (including gambling disorder, eating disorder, and body dysmorphic disorder), pain, neurodegenerative disorders (such as dementia, Alzheimer's Disease, Parkinson's Disease), autism spectrum disorder, eating disorders, or neurological disorders (such as stroke).
  • anxiety disorders including anxiety in advanced stage illness e.g. cancer, as well as generalized anxiety disorder
  • depression including postpartum depression, major depressive disorder and treatment-resistant depression
  • headache disorder including cluster headaches and migraine headache
  • a single pot granulation process called moisture activated dry granulation (MADG) was used for formulating low dose LSD in order to achieve suitable content uniformity and avoid a separate active drying step that would typically be performed with wet granulation.
  • MADG moisture activated dry granulation
  • the method of making LSD formulations includes: 1) Creating a granulation liquid stock solution of LSD, water (or other suitable solvent), and solubility aids if needed; 2) Blending a filler (i.e. mannitol) and binder (i.e. hydroxypropyl methylcellulose); 3) Spraying the granulation liquid onto the dry mixture and blending to form an agglomeration; 4) Adding a moisture absorbent (i.e.
  • the final granulation powder can be encapsulated or formed into tablets.
  • TABLE 1 shows 25 ⁇ g LSD (equivalent to 36.6 ⁇ g of d-LSD D-tartrate) formulations developed with microcrystalline cellulose and starch as absorbents in the MADG process. These formulations were encapsulated, placed on stability at 25° C., and tested for total impurities.
  • TABLE 2 shows total impurity results for the microcrystalline cellulose formulation and TABLE 3 shows total impurity results for the starch formulation.
  • FIG. 3 shows the dissolution profile for the starch containing formulation, which demonstrates immediate release of LSD or complete dissolution within 15 minutes.
  • TABLE 2 shows total impurities data of d-LSD D-tartrate using a MADG formulation with microcrystalline cellulose as the adsorbent.
  • TABLE 3 shows stability data of d-LSD D-tartrate using a MADG formulation with pregelled starch as the absorbent and FIG. 3 shows dissolution data.
  • FIG. 2 shows content uniformity of the pregelled starch formulation without a lubricant.
  • the process capability based on these results indicates that less than 0.5 parts-per-million (ppm) capsules would be outside the 85%-115% label claim range.
  • the data provides evidence that the uniformity of the final blend was satisfactory.
  • TABLE 4 shows the chemical stability data for the pregelled starch formulation without a lubricant at 25° C.
  • the method for making dry blend formulations of LSD in a single pot includes adding a minimum filler/carrier excipients, such as mannitol, lactose, and microcrystalline cellulose and d-LSD D-tartrate to a mixing vessel and blending until the drug is uniformly dispersed.
  • a minimum filler/carrier excipients such as mannitol, lactose, and microcrystalline cellulose and d-LSD D-tartrate
  • FIG. 4 shows the % iso-LSD, a known LSD degradation product, versus condition and excipient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Ceramic Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US17/890,198 2021-08-19 2022-08-17 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS Pending US20230064429A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US17/890,198 US20230064429A1 (en) 2021-08-19 2022-08-17 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US18/077,096 US20230107398A1 (en) 2021-08-19 2022-12-07 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US18/199,244 US20230285386A1 (en) 2021-08-19 2023-05-18 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163234773P 2021-08-19 2021-08-19
US17/890,198 US20230064429A1 (en) 2021-08-19 2022-08-17 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/077,096 Continuation US20230107398A1 (en) 2021-08-19 2022-12-07 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS

Publications (1)

Publication Number Publication Date
US20230064429A1 true US20230064429A1 (en) 2023-03-02

Family

ID=85239753

Family Applications (7)

Application Number Title Priority Date Filing Date
US17/890,198 Pending US20230064429A1 (en) 2021-08-19 2022-08-17 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US17/890,133 Active US12527786B2 (en) 2021-08-19 2022-08-17 Immediate release formulations of d-lysergic acid diethylamide for therapeutic applications
US18/077,096 Abandoned US20230107398A1 (en) 2021-08-19 2022-12-07 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US18/077,085 Active US12521385B2 (en) 2021-08-19 2022-12-07 Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
US18/194,761 Active US12036220B2 (en) 2021-08-19 2023-04-03 Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
US18/199,244 Pending US20230285386A1 (en) 2021-08-19 2023-05-18 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US19/276,575 Pending US20250345323A1 (en) 2021-08-19 2025-07-22 LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS

Family Applications After (6)

Application Number Title Priority Date Filing Date
US17/890,133 Active US12527786B2 (en) 2021-08-19 2022-08-17 Immediate release formulations of d-lysergic acid diethylamide for therapeutic applications
US18/077,096 Abandoned US20230107398A1 (en) 2021-08-19 2022-12-07 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US18/077,085 Active US12521385B2 (en) 2021-08-19 2022-12-07 Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
US18/194,761 Active US12036220B2 (en) 2021-08-19 2023-04-03 Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
US18/199,244 Pending US20230285386A1 (en) 2021-08-19 2023-05-18 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US19/276,575 Pending US20250345323A1 (en) 2021-08-19 2025-07-22 LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS

Country Status (8)

Country Link
US (7) US20230064429A1 (https=)
EP (2) EP4387624A4 (https=)
JP (2) JP7846211B2 (https=)
AU (4) AU2022331315B2 (https=)
CA (2) CA3229017A1 (https=)
IL (2) IL310591A (https=)
TW (3) TWI865366B (https=)
WO (2) WO2023023192A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12521385B2 (en) 2021-08-19 2026-01-13 Mind Medicine, Inc. Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
US12534460B2 (en) 2021-04-30 2026-01-27 Mind Medicine, Inc. LSD salt crystal forms
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine
CN117224540A (zh) * 2023-11-08 2023-12-15 迪沙药业集团有限公司 一种盐酸多奈哌齐的药物组合物
WO2025128594A1 (en) * 2023-12-11 2025-06-19 Mind Medicine, Inc. Methods of treating generalized anxiety disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145193A1 (en) * 2015-03-10 2016-09-15 Eleusis Benefit Corporation, Pbc Lsd for the treatment of alzheimer's disease

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2090430A (en) 1937-08-17 Lysergic acid amides and process for
US2447214A (en) 1948-08-17 Hoocxchoxxchoxxcooh
US1394233A (en) 1921-10-18 Arthur stoll
US3085092A (en) 1963-04-09 Preparation of lysergic acid deriva-
US2774763A (en) 1956-12-18 Preparation of amides of lysergic age
US2265207A (en) 1941-12-09 D-lysergic acid - d - l-bjtdroxybutyl
US2090429A (en) 1937-08-17 Lysergic acid hydkazide and a
US2438259A (en) 1948-03-23 D-lysergic acid diethyl amide
GB579484A (en) 1943-04-30 1946-08-06 Sandoz Ltd Process for the preparation of diethylamide of d-lysergic acid
US2809920A (en) 1953-04-10 1957-10-15 Saul & Co Process for the preparation of ergotamine, ergotaminine and ergometrine by saprophytic culture of ergot (claviceps purpurea [fr] tul.) in vitro and isolation of the alkaloids thus produced
US2796419A (en) 1954-09-27 1957-06-18 Lilly Co Eli Lysergic acid, intermediates and preparation
US2736728A (en) 1954-12-06 1956-02-28 Lilly Co Eli Preparation of lysergic acid amides
US2997470A (en) 1956-03-05 1961-08-22 Lilly Co Eli Lysergic acid amides
US3038840A (en) 1959-07-07 1962-06-12 Farmaceutici Italia Process for the production of alkaloid derivatives of lysergic acid
FR1338023A (fr) 1962-10-15 1963-09-20 Farmaceutici Italia Nouveau procédé de préparation d'amides d'acide lysergique, substituées ou non
US3239530A (en) 1964-01-13 1966-03-08 Sandoz Ltd Process for lysergic acid hydrazides
CH535236A (de) 1970-06-19 1973-03-31 Sandoz Ag Verfahren zur Herstellung neuer reaktionsträger Lysergsäurederivate
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
CA2134611C (en) 1994-10-28 2002-12-24 Richard John Yarwood Process for preparing solid pharmaceutical dosage forms
US6063908A (en) 1996-07-02 2000-05-16 Roche Diagnostics Corporation Reagents for lysergic acid diethylamide immunoassay
US20020028942A1 (en) * 1997-01-15 2002-03-07 Jacewicz Victor Witold Novel process and compound
CA2347469C (en) 1998-10-14 2006-02-28 Aventis Pharmaceuticals Inc. Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 100,907
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1248832A4 (en) 2000-01-21 2004-07-07 Variagenics Inc IDENTIFICATION OF THE GENETIC COMPONENTS OF A MEDICINE REACTION
US6794496B2 (en) 2000-04-07 2004-09-21 Roche Diagnostics Corporation Immunoassay for LSD and 2-oxo-3-hydroxy-LSD
AU2002237548B2 (en) * 2001-03-06 2007-04-05 Kyowa Hakko Kogyo Co., Ltd. Intraorally rapidly disintegrable tablet
ATE496917T1 (de) 2001-12-20 2011-02-15 Randox Lab Ltd Haptene, immunogene, antikörper und konjugate für 2-oxo-3-hydroxy lsd
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
JP5348840B2 (ja) 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 薬物を選択する方法
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
WO2005115473A2 (en) * 2004-05-24 2005-12-08 Nutrinia Ltd. Nutritional food and feed, composition, processing and method of use
ES2651021T3 (es) 2004-07-24 2018-01-23 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos activos sobre el receptor sigma para el tratamiento de alodinia mecánica
US20060039890A1 (en) 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
JP2006124282A (ja) 2004-10-26 2006-05-18 Central Glass Co Ltd ３，３，３−トリフルオロプロピオン酸の製造方法
US20060167481A1 (en) 2005-01-25 2006-07-27 Esophyx, Inc. Slitted tissue fixation devices and assemblies for deploying the same
US20060223998A1 (en) 2005-03-30 2006-10-05 Fang-Jie Zhang Synthetic LSD metabolite for preparing haptens used in an LSD metabolite immunoassay
GB0511060D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
CN101460150B (zh) * 2006-03-31 2014-02-12 鲁比康研究私人有限公司 用于口腔崩解片剂的可直接压片复合物
HRP20130713T1 (en) 2007-03-19 2013-09-30 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
CN101932577B (zh) 2007-11-30 2013-07-17 拜耳知识产权有限责任公司 杂芳基取代的哌啶
US9642819B2 (en) 2008-07-10 2017-05-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
JP5690732B2 (ja) * 2008-09-17 2015-03-25 ザ マクリーン ホスピタル コーポレーション 群発頭痛障害を治療するための方法及びキット
WO2010088911A1 (en) 2009-02-06 2010-08-12 Egalet A/S Pharmaceutical compositions resistant to abuse
US10548839B2 (en) * 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
CA2816551A1 (en) 2010-11-03 2012-05-10 Mcmaster University Method of treating mucosal inflammation
WO2014059197A1 (en) 2012-10-10 2014-04-17 Henkin Robert I Methods and compositions for diagnosing and treating hyposmia
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20170253928A1 (en) 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
CN113616883B (zh) 2014-06-30 2023-06-06 Syqe医药有限公司 向受试者肺部递送植物材料中的至少一药理活性剂的系统
KR20170040800A (ko) 2014-08-13 2017-04-13 얀센 파마슈티카 엔.브이. 우울증 치료 방법
EP2990029A1 (en) * 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
CN107206093A (zh) 2015-01-28 2017-09-26 韩国真耐瑞斯有限公司 用于治疗神经精神类障碍的组合物及方法
WO2016168891A1 (en) 2015-04-18 2016-10-27 Baycrest Technology Pty Ltd Medication dosing report
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
WO2017066488A1 (en) 2015-10-13 2017-04-20 Charleston Laboratories, Inc. Treating pain using a composition comprising an opioid and an antiemetic
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US20200222656A1 (en) 2016-10-18 2020-07-16 Joseph Rustick Method for treatment of depression using synaptic pathway training
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
US20190142851A1 (en) 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
NZ757591A (en) 2017-03-30 2026-03-27 Ojai Energetics Pbc Methods and compositions for enhancing health
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
JP2021500948A (ja) 2017-10-19 2021-01-14 エレウシス ヘルス ソリューションズ ユーエス インコーポレイテッド サイケデリック薬剤療法の安全性を向上させる方法およびシステム
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
CA3081626A1 (en) 2017-11-07 2019-05-16 MedReleaf Corp. Dosage and varietal recommendations for the treatment of medical conditions using cannabis
US11367103B2 (en) 2020-03-02 2022-06-21 Yieldmo, Inc. Method for modeling digital advertisement consumption
CA3148256A1 (en) 2018-06-21 2019-12-26 Robert John Petcavich Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
WO2020024977A1 (zh) 2018-08-01 2020-02-06 陕西麦科奥特科技有限公司 用于治疗神经系统疾病的化合物及其应用
MA54877A (fr) 2019-01-30 2021-12-08 Diamond Therapeutics Inc Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
FI4349407T3 (fi) 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
CA3132731A1 (en) 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
JP2022530390A (ja) 2019-04-24 2022-06-29 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 抗精神病剤の応答を予測するための方法
AU2020274186A1 (en) 2019-05-14 2021-12-09 The Scripps Research Institute Compounds for the treatment of neurodegenerative and metabolic disorders
US20220304980A1 (en) 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
GB201911024D0 (en) 2019-08-01 2019-09-18 Beckley Found Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
BR112022002723A2 (pt) 2019-08-13 2022-07-19 Univ Maryland Métodos de tratamento de transtornos psicológicos e do cérebro
US11246860B2 (en) 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression
JP2023515616A (ja) 2020-02-28 2023-04-13 ユニヴェルシテートスピタル バーゼル ５ｈｔ２ａアゴニストの投与後の抑制効果
GB202003059D0 (en) 2020-03-03 2020-04-15 Beckley Found Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain
CA3175211A1 (en) 2020-04-13 2021-10-21 Matthias Emanuel LIECHTI Lsd dose identification
MX2022012537A (es) 2020-04-16 2022-11-07 Pike Therapeutics Inc Entrega transdermica de microdosis de derivados psicodelicos.
US20230210762A1 (en) 2020-05-01 2023-07-06 Emergex USA Corporation Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
WO2021225796A1 (en) 2020-05-05 2021-11-11 Universitätsspital Basel Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics
WO2021243461A1 (en) 2020-06-04 2021-12-09 Neonmind Biosciences Inc. Use of lsd, esa, or dmt for weight loss.
BR112022025317A2 (pt) 2020-06-15 2023-01-03 Univ Basel Método de dosagem de um empatógeno/entactógeno no tratamento de pacientes; método para determinar uma dose de um empatógeno/entactógeno com base no peso corporal, sexo e atividade de cyp2d6; método para refinar a dosagem de um empatógeno/entactógeno; método para predizer a dosagem futura com um empatógeno/entactógeno; método para avaliar a viabilidade de pacientes para receber um empatógeno/entactógeno como tratamento; e método para otimizar o tratamento com empatógeno/entactógeno em um paciente
EP4167992A1 (en) 2020-06-22 2023-04-26 University of Zürich Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
US20210407643A1 (en) 2020-06-25 2021-12-30 Greenway Dna Inc. Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds
US20230286975A1 (en) 2020-07-07 2023-09-14 Compass Pathfinder Limited Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof
EP4188382A4 (en) 2020-07-29 2024-08-14 The Royal Institution for the Advancement of Learning / McGill University Administration of modulators of 5-ht and/or ampa receptors for treating neurological conditions
WO2022023812A1 (en) 2020-07-29 2022-02-03 Diamond Therapeutics Inc. Extended release 5-ht receptor agonists for neurological conditions
JP7584066B2 (ja) 2020-08-06 2024-11-15 株式会社一志精工電機 金型構造、プレス加工装置、およびプレス加工方法
DE202020105085U1 (de) 2020-09-03 2020-11-30 Sophie-Charlotte Adler Therapiemethode in Kombination mit psychoaktiver Zusammensetzung
CN116391128B (zh) 2020-10-24 2025-11-21 巴塞尔大学医院 人血浆中麦角酸二乙基酰胺（lsd）和2,3-二氢-3-羟基-2-氧代麦角二乙胺（o-h-lsd）的定量方法
WO2022107095A1 (en) 2020-11-22 2022-05-27 Havn Life Sciences Inc. Methods and compositions for treating pain with 2-bromo-lysergic acid diethylamide and thymoquinone
WO2022115796A1 (en) 2020-11-30 2022-06-02 Wesana Health Inc. Compositions and methods for treating neurological conditions
CA3203642A1 (en) 2020-12-02 2022-06-09 The Johns Hopkins University Restoration of motor function post-neurological injury using psychedelics
EP4155306A1 (en) 2021-01-15 2023-03-29 Beckley Psytech Limited Neuroactive ergoline analogue
US20220273628A1 (en) 2021-02-19 2022-09-01 Universitätsspital Basel Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
EP4301464A1 (en) 2021-03-06 2024-01-10 Universitätsspital Basel Using geno- or phenotyping to adjust lsd dosing
CA3215871A1 (en) 2021-03-31 2022-10-06 Lyfe Chng, Llc Transdermal system, formulation, and method for the therapeutic administration of a psychedelic agent
WO2022221942A1 (en) 2021-04-19 2022-10-27 Betterlife Pharma Inc. Prevention of drug diversion
US20230116703A1 (en) 2021-04-23 2023-04-13 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
US20240368151A1 (en) 2021-04-23 2024-11-07 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
JP2024517194A (ja) 2021-05-03 2024-04-19 マインド メディシン， インコーポレイテッド サイケデリック薬の用量を漸増する方法
US20220362237A1 (en) 2021-05-03 2022-11-17 Mind Medicine, Inc. Psychedelics for treatment of pain
WO2022235500A1 (en) 2021-05-03 2022-11-10 Mind Medicine, Inc. Psychedelics for treatment of pain
US20230301985A1 (en) 2021-05-04 2023-09-28 Mind Medicine, Inc. Movement disorders
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders
BR112023024688A2 (pt) * 2021-05-26 2024-02-15 Mindset Pharma Inc Combinação de halucinógeno-ácido graxo
WO2022261058A1 (en) 2021-06-07 2022-12-15 University Of Mississippi Methods for the pulsed delivery of bioactive agents
WO2022265878A1 (en) 2021-06-14 2022-12-22 Mind Medicine, Inc. Controlling effects after 5ht2a agonists administration
EP4366729A4 (en) 2021-07-07 2025-06-11 Arcadia Medicine, Inc. SAFER PSYCHOACTIVE COMPOSITIONS
WO2023012691A1 (en) 2021-08-03 2023-02-09 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
WO2023012524A2 (en) 2021-08-03 2023-02-09 Universitatsspital Basel Lsd and psilocybin dose equivalence determination
JP7846211B2 (ja) 2021-08-19 2026-04-14 デフィニウム セラピューティクス ユーエス， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
WO2023043870A1 (en) 2021-09-15 2023-03-23 Eleusis Therapeutics Us, Inc. Chewing gum formulation of lsd and methods of use thereof
KR20240088949A (ko) 2021-09-20 2024-06-20 비라이프 테라퓨틱스 인크. 질병 및 질환의 치료를 위한 lsd 유도체, 합성 및 방법
WO2023107966A1 (en) 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of lysergic acid diethylamide (lsd) and analogs
WO2023108277A1 (en) 2021-12-14 2023-06-22 Agile Pharmaceuticals Solutions Inc. Cannabinoid and psychedelic formulations comprising hydrotropic agents
US20250109130A1 (en) 2021-12-16 2025-04-03 Terran Biosciences Inc. Isotopically enriched analogs of 2-bromo-lsd, lsd, ald-52, and 1p-lsd
WO2023114529A2 (en) 2021-12-17 2023-06-22 Bennes, Inc. Pharmacoactive formulations for delivery of psychedelic compounds
WO2023183618A1 (en) 2022-03-25 2023-09-28 Ojai Energetics Pbc Psychedelic compositions and methods for forming the same
US20250295611A1 (en) 2022-04-27 2025-09-25 Tessellate Therapeutics Inc. Methods of treating 5ht2a receptor-mediated conditions
US20230346645A1 (en) 2022-05-01 2023-11-02 Mind Medicine, Inc. Method of titrating dose of psychedelics
JP2025525375A (ja) 2022-06-20 2025-08-05 マインド メディシン， インコーポレイテッド 修飾ｌｓｄ様作用を有するリゼルグ酸誘導体
US20260034058A1 (en) 2022-08-09 2026-02-05 Vitalmelt Ltd. Freeze-dried bite with single dose psychedelic
WO2024229454A2 (en) 2023-05-04 2024-11-07 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
WO2024238035A1 (en) 2023-05-16 2024-11-21 Mind Medicine, Inc. Movement disorders
US20250312309A1 (en) 2023-06-22 2025-10-09 Mind Medicine, Inc. Allyl-and propargylamine-type phenethylamines and tryptamines for treating medical disorders
WO2025128594A1 (en) 2023-12-11 2025-06-19 Mind Medicine, Inc. Methods of treating generalized anxiety disorder

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145193A1 (en) * 2015-03-10 2016-09-15 Eleusis Benefit Corporation, Pbc Lsd for the treatment of alzheimer's disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
am Ende et al. "Improving the Content Uniformity of a Low-Dose Tablet Formulation Through Roller Compaction Optimization," Pharmaceutical Development and Technology, 12:391–404, 2007 (Year: 2007) *
Moravkar et al. "Application of moisture activated dry granulation (MADG) process to develop high dose immediate release (IR) formulations," Advanced Powder Technology 28 (2017) 1270–1280 (Year: 2017) *
Sharma et al. "Review on Moisture activated Dry Granulation Process," PharmaTutor; 2017; 5(12); 58-67 (Year: 2017) *
Takasaki et al. "Importance of excipient wettability on tablet characteristics prepared by moisture activated dry granulation (MADG)," International Journal of Pharmaceutics 456 (2013) 58– 64 (Year: 2013) *
Ullah et al. "Moisture-Activated Dry Granulation-Part I: A Guide to Excipient and Equipment Selection and Formulation Development," Pharmaceutical Technology-11-02-2009, Volume 33, Issue 11. (Year: 2009) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12534460B2 (en) 2021-04-30 2026-01-27 Mind Medicine, Inc. LSD salt crystal forms
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders
US12521385B2 (en) 2021-08-19 2026-01-13 Mind Medicine, Inc. Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
US12527786B2 (en) 2021-08-19 2026-01-20 Mind Medicine, Inc. Immediate release formulations of d-lysergic acid diethylamide for therapeutic applications

Also Published As

Publication number Publication date
TWI865366B (zh) 2024-12-01
EP4387623A4 (en) 2025-07-02
US20230285386A1 (en) 2023-09-14
WO2023023182A1 (en) 2023-02-23
AU2022331315A1 (en) 2024-02-22
CA3229017A1 (en) 2023-02-23
JP2024529728A (ja) 2024-08-08
AU2022331317A1 (en) 2024-02-29
AU2022331317B2 (en) 2025-09-11
US12036220B2 (en) 2024-07-16
WO2023023192A1 (en) 2023-02-23
US20230122949A1 (en) 2023-04-20
EP4387624A4 (en) 2025-07-30
AU2026200219A1 (en) 2026-01-29
JP2024529727A (ja) 2024-08-08
TWI838826B (zh) 2024-04-11
TW202317116A (zh) 2023-05-01
US12521385B2 (en) 2026-01-13
EP4387624A1 (en) 2024-06-26
US12527786B2 (en) 2026-01-20
TW202434244A (zh) 2024-09-01
IL310569A (en) 2024-03-01
JP7846211B2 (ja) 2026-04-14
CA3228975A1 (en) 2023-02-23
US20250345323A1 (en) 2025-11-13
US20230075847A1 (en) 2023-03-09
TW202315627A (zh) 2023-04-16
EP4387623A1 (en) 2024-06-26
US20230107398A1 (en) 2023-04-06
US20230218532A1 (en) 2023-07-13
AU2022331315B2 (en) 2025-10-16
AU2025275308A1 (en) 2026-01-15
IL310591A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
US20230064429A1 (en) IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
JP5421775B2 (ja) オキシコドンを含む顆粒及び口腔内崩壊錠剤
CA3097053C (en) Edaravone pharmaceutical composition
US20160000720A1 (en) Pharmaceutical compositions comprising Tadalafil
EP1778195A2 (en) Anti-histaminic composition
WO2025195452A1 (zh) 一种艾沙康唑药物组合物及其制备方法
CN110582278B (zh) 药物组合物及其用途
GB2573784A (en) A stable aqueous hydroxycarbamide solution
CN121360090A (zh) 一种孟鲁司特钠咀嚼片及其制备方法和应用
WO2025046526A1 (ko) 설트랄린 또는 이의 염을 포함하는 약학적 조성물
JPWO2007049626A1 (ja) カベルゴリン含有経口固形製剤
HK40029191A (en) Composition of aminopyran derivative
JP2006265183A (ja) ペルゴリド錠剤の製造方法

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: MIND MEDICINE, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MACK, PETER;MELTON, DUSTIN;DOTY, BETHANY AMBER;AND OTHERS;SIGNING DATES FROM 20221027 TO 20221113;REEL/FRAME:061794/0152

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER